Since the Food and Drug Administration approved BSP, no nationally representative population-based studies have examined the outcomes and adverse events.

Researchers conducted this study to assess the rates of complications and revision surgery in patients who received BSP, FESS, or a hybrid procedure.

Using one of the nation’s largest commercial insurance databases, we conducted a retrospective cohort study of pediatric and adult patients diagnosed with chronic rhinosinusitis between 2011 and 2014 who underwent BSP, conventional FESS, or a hybrid procedure. The primary outcomes were surgical complication and revision rates within six months of initial surgery.

A total of 16,040 patients who underwent sinus surgery were included. Overall, 2,851 patients underwent BSP, 11,955 underwent conventional FESS, and 1 234 underwent a hybrid procedure. BSP surgery was more likely to have been performed in an office setting than FESS. The complication rate was 5.26% for BSP and 7.35% for conventional FESS. Revision rates were 7.89% for BSP, 16.85% for FESS, and 15.15% for a hybrid procedure.

The study concluded that significant complications occur with BSP, including cerebrospinal fluid leak, pneumocephalus, orbital complications, and severe bleeding despite the low overall risk.